Atara Biotherapeutics Faces Regulatory Setback for EBVALLO™ Approval Amid Compliance Issues

Atara Biotherapeutics Faces Regulatory Hurdle for EBVALLO™ Approval

Atara Biotherapeutics, Inc. encounters a significant setback as the U.S. Food and Drug Administration (FDA) issues a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for its T-cell immunotherapy, EBVALLO™ (tabelecleucel). This therapy is aimed at treating adult and pediatric patients over the age of two with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). The CRL arises from observations made during a routine pre-license inspection of a third-party manufacturing facility, signaling compliance issues rather than concerns over the manufacturing process, clinical efficacy, or safety data. This distinction is crucial as it means Atara does not need to conduct new clinical trials to move forward.

Atara’s Chief Executive Officer, Cokey Nguyen, notes that the company is actively working alongside Pierre Fabre Laboratories, the FDA, and the third-party manufacturer to address the regulatory feedback. With a commitment to resolve the compliance issues, Atara plans to resubmit the BLA for EBVALLO potentially within the next six months. The urgency of this resubmission is underscored by the fact that EBVALLO has already received authorization from the European Commission in December 2022, where it demonstrated a promising 50% Objective Response Rate (ORR) based on results from the pivotal ALLELE study. These achievements highlight the product’s potential in addressing a critical unmet medical need for patients suffering from a rare and often life-threatening condition.

The manufacturing landscape for EBVALLO is also evolving, with the FUJIFILM Diosynth Biotechnologies facility in Thousand Oaks, California, recently receiving approval from the European Medicines Agency (EMA) to produce the therapy. This approval is integral to Atara's global manufacturing strategy and ensures that the company can meet future demand as it seeks to bring EBVALLO to the U.S. market. Despite the disappointment expressed by Pierre Fabre’s CEO, Eric Ducournau, regarding the delay, he assures stakeholders that both companies remain committed to collaborating for the therapy's success in the United States.

In the wake of the CRL, Atara continues to explore strategic alternatives while remaining steadfast in its mission to tackle significant unmet medical needs. The company’s focus on collaboration and rapid resubmission reflects its commitment to navigating regulatory challenges, ultimately aiming to provide innovative solutions for patients in urgent need of effective therapies.